Lakeside Holding (LSH) subsidiary Hupan Pharmaceutical has signed a Sales Agreement with Sinopharm Holding Hubei New Special Medicine, a subsidiary of Sinopharm Group. The agreement, valued at approximately $1.5M, is effective from January 1, 2025, through the end of the year and involves the sale and delivery of critical medicines, including Sodium Bicarbonate, Glucose, and Glucose Sodium Chloride. This Agreement follows the partnership with Sinopharm Group announced last month focusing on essential medicine storage, transportation, and logistics services.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio